About KINERET® (anakinra)
KINERET is a very specific treatment for a very specific RA patient.
RA that is primarily autoinflammatory may be mediated by interleukin-1 (IL-1), cytokines produced by cells in the innate immune system. KINERET is an IL-1 receptor antagonist, blocking an underlying cause of inflammation in difficult-to-treat RA.1
The effects of IL-1
Elevated levels of IL-1 may be responsible for some of the hallmarks of RA, such as1:
- Cartilage degradation
- Bone resorption
- Other autoinflammatory symptoms
KINERET is the only FDA-approved RA treatment that blocks both IL-1α and IL-1β.1
Watch the video to see KINERET in action.
An in-depth look at the data.
In a 2004 study, 6% of KINERET-treated patients achieved ACR70.1
In a randomized, double-blind, placebo-controlled trial of 899 patients with active RA who had been on a stable dose of methotrexate (10 to 25 mg/week) for at least 8 weeks. Patients were randomized to KINERET (n=250) or placebo (n=251) in addition to their stable doses of methotrexate. The first 501 patients were evaluated for signs and symptoms of active RA.
Patients using KINERET saw improvements in ACR component scores.1
A 24-week study was conducted in 242 patients with active RA on background methotrexate who were randomized to receive either etanercept alone or the combination of KINERET and etanercept. The ACR50 response rate was 31% for patients treated with the combination of KINERET and etanercept and 41% for patients treated with etanercept alone, indicating no added clinical benefit of the combination over etanercept alone. Serious infections were increased with the combination compared to etanercept alone [see Warnings and Precautions (5.1) in the full Prescribing Information].
|MEDIAN ACR COMPONENT SCORES|
|PLACEBO / MTX(n=251)||KINERET (anakinra) / MTX 100 mg/day ( n=250 )|
|parameter (median)||baseline||month 6||baseline||month 6|
|Patient global assessmentb||51.0||41.0||51.0||29.0|
|Physician global assessmentb||59.0||31.0||59.0||26.0|
a Health Assessment Questionnaire; 0 = best, 3 = worst; includes eight categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities. b Visual analog scale; 0 = best, 100 = worst c Scale 0 to 68
Consider KINERET for patients with complicating conditions.
The safety profile of KINERET was demonstrated in a high-risk RA patient population and shown to be well-tolerated among those with1:
- Varying degrees of disease activity
- Concurrent medications
- History of complicating conditions, including:
- Chronic obstructive pulmonary disease